Suppr超能文献

肝细胞癌治疗后患者的治疗后监测影像学应用的趋势和模式。

Trends and patterns of utilization in post-treatment surveillance imaging among patients treated for hepatocellular carcinoma.

机构信息

Department of Surgery, Johns Hopkins University School of Medicine, Blalock 688 600N. Wolfe Street, Baltimore, MD 21287, USA.

Department of Medical Oncology, Johns Hopkins University School of Medicine, Blalock 688 600N. Wolfe Street, Baltimore, MD 21287, USA.

出版信息

J Gastrointest Surg. 2013 Oct;17(10):1774-1783. doi: 10.1007/s11605-013-2302-6. Epub 2013 Aug 14.

Abstract

BACKGROUND

Little is known about the patterns of utilization of surveillance imaging after treatment of hepatocellular carcinoma (HCC). We sought to define population-based patterns of surveillance and investigate if intensity of surveillance impacted outcome following HCC treatment.

METHODS

The Surveillance, Epidemiology, and End Results-Medicare database was used to identify patients with HCC diagnosed between 1998 and 2007 who underwent resection, ablation, or intra-arterial therapy (IAT). The association between imaging frequency and long-term survival was analyzed.

RESULTS

Of the 1,467 patients, most underwent ablation only (41.5%), while fewer underwent liver resection only (29.6 %) or IAT only (18.3%). Most patients had at least one CT scan (92.7%) during follow-up, while fewer had an MRI (34.1%). A temporal trend was noted with more frequent surveillance imaging obtained in post-treatment year 1 (2.5 scans/year) vs. year 5 (0.9 scans/year; P = 0.01); 34.5% of alive patients had no imaging after 2 years. Frequency of surveillance imaging correlated with procedure type (total number of scans/5 years, resection, 4.7; ablation, 4.9; IAT, 3.7; P < 0.001). Frequency of surveillance imaging was not associated with a survival benefit (three to four scans/year, 49.5 months vs. two scans/year, 71.7 months vs. one scan/year, 67.6 months; P = 0.01) CONCLUSION: Marked heterogeneity exists in how often surveillance imaging is obtained following treatment of HCC. Higher intensity imaging does not confer a survival benefit.

摘要

背景

肝癌(HCC)治疗后监测成像的利用模式知之甚少。我们旨在确定基于人群的监测模式,并研究监测强度是否会影响 HCC 治疗后的结果。

方法

使用监测、流行病学和最终结果-医疗保险数据库来确定 1998 年至 2007 年间接受切除术、消融术或肝内动脉治疗(IAT)的 HCC 诊断患者。分析成像频率与长期生存之间的关联。

结果

在 1467 名患者中,大多数仅接受消融术(41.5%),而较少接受肝切除术(29.6%)或 IAT 仅(18.3%)。大多数患者在随访期间至少进行了一次 CT 扫描(92.7%),而较少进行 MRI(34.1%)。在治疗后第 1 年(每年 2.5 次扫描)与第 5 年(每年 0.9 次扫描),监测成像的频率呈增加趋势(P=0.01);2 年后,34.5%的存活患者没有进行影像学检查。监测成像的频率与手术类型相关(5 年内的总扫描次数,切除术为 4.7;消融术为 4.9;IAT 为 3.7;P<0.001)。监测成像的频率与生存获益无关(每年 3 至 4 次扫描,49.5 个月;每年 2 次扫描,71.7 个月;每年 1 次扫描,67.6 个月;P=0.01)。

结论

在 HCC 治疗后监测成像的获取频率存在显著异质性。更高强度的成像并不能带来生存获益。

相似文献

1
Trends and patterns of utilization in post-treatment surveillance imaging among patients treated for hepatocellular carcinoma.
J Gastrointest Surg. 2013 Oct;17(10):1774-1783. doi: 10.1007/s11605-013-2302-6. Epub 2013 Aug 14.
2
Postoperative imaging surveillance for hepatocellular carcinoma: How much is enough?
J Surg Oncol. 2021 Jun;123(7):1568-1577. doi: 10.1002/jso.26433. Epub 2021 Feb 17.
4
Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables.
Eur J Surg Oncol. 2010 Mar;36(3):275-80. doi: 10.1016/j.ejso.2009.10.001. Epub 2009 Oct 25.
6
Surgical resection versus ablation for hepatocellular carcinoma ≤ 3 cm: a population-based analysis.
HPB (Oxford). 2015 Oct;17(10):896-901. doi: 10.1111/hpb.12446. Epub 2015 Jul 31.
7
Prediagnostic CT or MRI Utilization and Outcomes in Hepatocellular Carcinoma: SEER-Medicare Database Analysis.
Cancer Res Commun. 2023 May 16;3(5):874-883. doi: 10.1158/2767-9764.CRC-23-0075. eCollection 2023 May.

引用本文的文献

1
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.
J Liver Cancer. 2023 Mar;23(1):1-120. doi: 10.17998/jlc.2022.11.07. Epub 2022 Dec 9.
2
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.
Korean J Radiol. 2022 Dec;23(12):1126-1240. doi: 10.3348/kjr.2022.0822.
3
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.
Clin Mol Hepatol. 2022 Oct;28(4):583-705. doi: 10.3350/cmh.2022.0294. Epub 2022 Oct 1.
5
Features of extrahepatic metastasis after radiofrequency ablation for hepatocellular carcinoma.
World J Gastroenterol. 2020 Aug 28;26(32):4833-4845. doi: 10.3748/wjg.v26.i32.4833.
8
Forecasting the demand for radiology services.
Health Syst (Basingstoke). 2017 Nov 7;7(2):79-88. doi: 10.1080/20476965.2017.1390056. eCollection 2018.

本文引用的文献

2
American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care.
J Clin Oncol. 2013 Feb 10;31(5):631-40. doi: 10.1200/JCO.2012.46.6854. Epub 2013 Jan 7.
3
Risk factors of post-operative recurrence and adequate surgical approach to improve long-term outcomes of hepatocellular carcinoma.
HPB (Oxford). 2013 Jan;15(1):31-9. doi: 10.1111/j.1477-2574.2012.00552.x. Epub 2012 Aug 26.
6
Surveillance of pancreatic cancer patients after surgical resection.
Ann Surg Oncol. 2012 May;19(5):1670-7. doi: 10.1245/s10434-011-2152-y. Epub 2011 Dec 6.
7
Is it worth looking? Abdominal imaging after pancreatic cancer resection: a national study.
J Gastrointest Surg. 2012 Jan;16(1):121-8. doi: 10.1007/s11605-011-1699-z. Epub 2011 Oct 5.
10
NCCN clinical practice guidelines in oncology: hepatobiliary cancers.
J Natl Compr Canc Netw. 2009 Apr;7(4):350-91. doi: 10.6004/jnccn.2009.0027.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验